New Parkinson’s Drug Shows Promise in Early Testing

ENERGI-F705PD, an investigational oral therapy from Taiwan-based Energenesis Biomedical, was found to be safe and well tolerated in a Phase 1 clinical trial involving 24 healthy volunteers. Unlike current treatments, which focus mainly on relieving symptoms, this therapy aims to address the underlying causes of Parkinson’s disease. Aiming to Slow or Stop Disease Progression Parkinson’s results from the gradual loss of dopamine-producing nerve cells, leading to both movement and non-movement symptoms. Current treatments manage these symptoms but do not slow or reverse the disease. ENERGI-F705PD is designed as a potential disease-modifying therapy, meaning it could help protect brain cells and slow progression. How It Works This therapy combines multiple strategies to tackle core problems in Parkinson’s: Boosting Cellular Energy: Increases ATP, the main energy molecule for cells. Reducing Protein Clumps: May prevent harmful alpha-synuclein buildup inside nerve cells. Enhancing Antioxidant Defenses: Strengthens nerve cells’ natural protection against damage. Supporting Dopamine Production: Increases activity of tyrosine hydroxylase, an enzyme key to making dopamine. Together, these mechanisms may help preserve brain function and slow neurodegeneration. Trial Results and Next Steps The Phase 1 trial confirmed a positive safety profile and validated the drug’s sustained-release design, which delivers the therapy slowly and continuously in the body. Encouraged by these results, Energenesis plans to begin a Phase 2 clinical trial in people with Parkinson’s and will submit an application to regulators later this year.